About Innocoll

Innocoll is a specialty pharmaceutical company committed to improving the status quo and finding answers to unmet needs

XARACOLL®

Our lead investigational product is a drug-device surgical implant being developed for potential uses in addressing postsurgical pain

Latest News

Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL® for the Management of Postsurgical Pain

- FDA Sets Prescription Drug User Fee Act (PDUFA) Goal Date of August 26, 2020- ATHLONE, Ireland, March 26, 2020...
Read More

Innocoll Holdings Limited Resubmits New Drug Application to FDA for XARACOLL® for the Management of Postsurgical Pain after Open Inguinal Hernia Surgery

ATHLONE, Ireland, Feb. 27, 2020 /PRNewswire/ -- Innocoll Holdings Limited, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, announced today that...
Read More

Innocoll Holdings Limited Appoints Richard Fante as Chief Executive Officer

ATHLONE, Ireland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Innocoll Holdings Limited (“Innocoll”), a specialty pharmaceutical company wholly owned by Gurnet Point Capital, announced...
Read More